



Open to Accrual

Low Accruing

Pending Activation

1L

UCI 24-192 (Nuvalent) NVL-655 vs Alectinib

Mechanism: ALK inhibitor Coord: Mindy Chen PI: Dr. Nagasaka Accrual: 0/5


> UCI 21-241 (Nuvalent) NVL-655 + ALK inhibitor


Mechanism: ALK Inhibitor Coord: Keagan Buttigieg PI: Dr. Nagasaka Accrual: 20/25 UCI 25-51 (Nuvalent

Mechanism: ALK inhibitor Coord: To be determined PI: Dr. Park Accrual: 0/7

2L









1L UCI 23-66 (Boehringer Ingelheim) BI-1810631 Monotherapy Mechanism: TKI Cord: Cassie Smith Dr. Nagasaka Accrual: 2/5 2L

Exon 18 Exon 19 Exon 20 Exon 21 UCI 24-169 (BlossomHill Therapeutics) BH-30643 Capsule Mechanism: EGFR or HER2 TKI Coord: Celest Ramirez PI: Dr. Nagasaka Accrual: 8/10 **UCI 23-178** BL-B01D1 IV Mechanism: EGFR and/or HER3 bispecific antibody Coord:Cassie Smith PI: Dr. Park Accrual: 5/10

HER2 Mutations





Open to Accrual



Low Accruing



Pending Activation

UCI 25-79 (Beamion Lung-3 Zongertinib vs SOC

> Mechanism: TKI d: To be determine PI: Dr. Arter Accrual: 0/3



11

UCI 22-30 (D3S-001-100): D3 Bio

Mechanism: TKI Coord: Cassie Smith Dr. Nagasaka Accrual: 3/5

UCI 25-88 (Part A:

2L

UCI 21-53 (Loxo Oncology, Inc. LOXO-RAS-20001

Mechanism: TKI Coord: Mindy Chen Dr. Nagasaka Accrual:9/12

UCI 24-157 (RMC-6236-301)

UCI 22-87 (RMC-6236 **Revolution Med)**

Mechanism: TKI Coordinator: Jenny Choe Dr. Nagasaka Accrual: 21/25

Open to Accrual

Low Accruing

Pending Activation

NTRK 1-3

1L

2L



Open to Accrual



Low Accruing



Pending Activation

UCI 25-52 (PYNNACLE) Rezatapopt (PC14586)

Mechanism: selective P53 reactiviator Coord: To be determined PI: Dr. Arter Accrual: 0/5





Advanced / Metastatic

1L

UCI 24-160 Chemo + Cemiplimab + Agent (a, b, or none)

> Mechanism: PD-L1 Coord: Mindy Chen PI: Dr. Nagasaka Accrual: 0/5

2L

PD-L1 Mutation

UCI 23-148: CJRB-01 (oral) + Pembrolizumab

Mechanism: Live biotherapeutic product + Pembrolizumab Coord: Mindy Chen PI: Dr. Nagasaka Accrual: 3/6





Mechanism: Coord: TBD PI: Dr. Park Accrual: 0/5

UCI 24-78 (AMG 193 Alone or Comb w/OtherTherapies)

Mechanism: Coord: Cassie Smith PI: Dr. Villalona Accrual: 1/5



UCI 24-138 (UCLA):

Mechanism: BiTE molecule Coord: TBD PI: Dr. Park Accrual: 0/5









Low Accruing



Pending Activation



ADVANCED/METASTATIC






Open to Accrual

Low Accruing

Pending Activation



Mechanism: Fecal Collection Coord: Stephanie Fernandez Pl: Dr. Nagasaka Accrual: 7/82 UCI 24-118 (Keshava IIT): Lung Cancer Family Screening

Mechanism: NA Coord: Stephanie Fernandez/ Mindy Chen Accrual: 12/1753



2L

Basket Trials

UCI 24-08 (SPEDOX-6): Dr. Chow IIT

Mechanism: SPE Coord: Erin Palmer-Torrison PI: Dr. Chow Accrual: 3/67 Crinetics Pharmaceuticals

Mechanism: NDC Coord: Michelle Andrade PI: Dr. Dayyani Accrual: 0/15

